Positive Patient Stories™

Investor Overview

Corporate Profile

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company’s lead FDA approved commercial product, NUZYRA™ (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment of adult patients with CABP and ABSSSI caused by susceptible pathogens. Paratek is also studying NUZYRA™ for the treatment of urinary tract infections (UTI).

Paratek has submitted a marketing authorization application for omadacycline in the European Union. Paratek has entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.

Paratek’s second FDA approved commercial product, SEYSARA™ (sarecycline), is marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. Paratek retains development and commercialization rights to sarecycline in the rest of the world.

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.22
Change (%) Stock is Down 0.01 (0.14%)
Volume199,651
Data as of 02/19/19 4:00 p.m. ET

Latest News

02/14/19
Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
02/13/19
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
02/06/19
New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
02/05/19
Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.